Back to News
Market Impact: 0.2
Guggenheim Upgrades Editas Medicine to Buy from Neutral
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Guggenheim upgraded Editas Medicine (NASDAQGS: EDIT) to Buy from Neutral on September 23, 2026. The rating change is a positive catalyst for the gene-editing biotechnology company, though the article provides no price target, financial estimates, or clinical-program details to quantify the underlying rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EDIT0.55
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- Top Wall Street analysts like these 3 dividend stocks for consistent income
- Crocs evp Rupert Campbell sells $399K of CROX stock
- MercadoLibre's Profits Fall Again. What It Means for Investors